Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 3,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Transmitted Diseases, Viral Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

NCT04303156
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

NCT00000981
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Fiacitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT

NCT00002302
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Atlanta, Georgia • Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 2Phase 3 Interventional

Study to Reduce Intravenous Exposures (STRIVE)

NCT00391482
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peer Mentoring Intervention for HCV-Infected IDUs
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 35 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

NCT03816696
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 17, 2026, 11:58 AM EDT
Not listed Not applicable Interventional

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

NCT01969461
View directory record Official record
Conditions
HIV
Interventions
Motivational Enhancement Therapy (MET)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 24 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

NCT00001386
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
PCLUS 3-18 MN, PCLUS 6.1 MN
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 11:58 AM EDT
Completed No phase listed Observational

The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study

NCT00824278
View directory record Official record
Conditions
Cancer, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 21 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

NCT00118378
View directory record Official record
Conditions
HIV Infections, Fatigue
Interventions
Modafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000878
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

NCT00002042
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
190
States / cities
Birmingham, Alabama • Hobson City, Alabama • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

NCT00594880
View directory record Official record
Conditions
HIV Infections
Interventions
Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

NCT00004580
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Drug Interaction of BI 201335 and Tenofovir

NCT01340196
View directory record Official record
Conditions
HIV Infections
Interventions
tenofovir/BI 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Not applicable Interventional

Rural PrEP Delivery

NCT03343223
View directory record Official record
Conditions
HIV/AIDS
Interventions
Intervention Group
Behavioral
Lead sponsor
Michael Ohl
Other
Eligibility
18 Years to 70 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 17, 2026, 11:58 AM EDT
Completed No phase listed Observational

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

NCT00004846
View directory record Official record
Conditions
Hepatitis C, HIV Infection
Interventions
ABC/Gen-Probe/Chiron HIV-1/HCV 001
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 11:58 AM EDT
Completed No phase listed Observational

Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

NCT00028145
View directory record Official record
Conditions
HIV Infections, Pregnancy Complications, Infectious
Interventions
Adherence assessment
Behavioral
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
14 Years and older · Female only
Enrollment
3,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 17, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

NCT01852942
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 17, 2026, 11:58 AM EDT
Recruiting Not applicable Interventional

SCOPE Analytic Treatment Interruption Protocol

NCT04359186
View directory record Official record
Conditions
HIV/AIDS
Interventions
Treatment Interruption Arm
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 11:58 AM EDT